|
| Reference | Engraf. failure | Med. days to neut./PLT eng. | aGVHD
II–IV/III-IV | cGVHD | NRM | Relapse | EFS/PFS | OS |
|
| O’Donnell et al., 2002 [24] | 20%
Cohort 2 | 15/14 | 46%/23% | 1/10 limited | 1/10 died of GVHD | 4/10 cohort 2 relapsed | At med. f/u 6 mo. 5/10 in CR | At med. f/u 6 mo. 6/10 (cohort 2) alive |
|
| Luznik et al., 2008 [25] | 13% | 15/24 | 34%/6% | Ext. 5% in 2 doses of CY versus 25% in one dose of Cy | 1 y 15% | 1 y 51% | 2 y EFS 26% | 2 y 36% |
|
| Symons et al., 2011 [26] | 4% | 25/32 | 14%/7.3% | 13% | 100 D 12% | 1 y 66% poor risk
1 y 13% in CR | 1 y 23.5% | 1 y 40% |
|
| Brunstein et al., 2011 [27] | 2% | 16/24 | 32%/0 | 1 y 13% | 1 y 7% | 1 y 45% | 1 y PFS 48% | 1 y 62% |
|
| Pingali et al., 2014 [28] | 4.7% | 18/NA | 32.6%/7.8% | 21.3%/Ext. 10% | 25% | 3 y 30.1% | 3 y PFS 42.3% | 1 y OS 64%
Median OS for 1st SCT 25.6 mo.
2nd SCT 6.5 mo. |
|
| Solomon et al., 2012 [29] | 0% | 16/27 | 30%/10% | 35%/severe 5% | 1 y 10% | 1 y 40% | 1 y DFS 50% | 1 y 69% |
|
| Raiola et al., 2013 [30] | 6% | 18/23 | 12%/6% | 26%/Ext. 0 | 6 mo. 18% | 18 mo. 22% | DFS 18 mo. 51% | 18 mo. 62% |
|
| Raj et al., 2014 [31] | 4% | 17/21 | II 35%
III 8%
IV 0% | 18% @ 2 y
2 severe cases | 1 y 17% | 2 y 28% | 2 y 51% | 2 y 48% |
|
| Bhamidipati et al., 2014 [32] | 6% | 15/18 | All grades 53%/17% | 8% @ 2 y
Ext. only in 1 patient | 1 y 17% | 1 y 38% | 1 y 53% | 1 y 62% |
|
|
Castagna et al., 2014 [33] | NA | BM 21/29 | 25%/3% | 13% | 2 y 19% | 1 y 22% | 2 y PFS 62% | 2 y 68% |
| NA | PB 20/27 | 33%/14% | 13% | 1 y 12% |
|
| Solomon et al., 2015 [34] | 0 | 16/25 | 43%/23% | 56%/Ext. 10% | 2 y 3% | 2 y 24% | 2 y DFS 73% | 2 y 78% |
|
|
Bradstock et al., 2015 [35] | 0 | 15/18 | I–III 55.1%
No IV | 28.6% | 6 mo. 0 | 2 y 43.9% | 2 y EFS 44.9% | 2 y 52.7% |
| 13% | 16/24 | I–III 48.5%
No IV | 32.3% | 6 mo. 0 | 2 y 23.5% | 2 y EFS
63.6% | 2 y 83.4% |
|
| Gayoso et al., 2013 [36] | NA | 18/27 | 33%/14% | 24%/Ext. 12% | 6 mo. 19% | NA | 1 y EFS
48% | 1 y 60% |
|
| Sugita et al., 2015 [37] | 13%
(0 in no h/o SCT; 31% in h/o SCT) | 19/35 | 23%/3% | 15%/none severe | 1 y 23% | 1 y 45% | 1 y DFS
34% | 1 y 45% |
|
